Nanobiotix ’s nanoparticle-immunotherapy trial wins FDA approval
Nanobiotix (EMA:NANO) said today that the FDA has approved its IND application for a cancer trial combining its radiotherapy-activated nanoparticle tech with an anti-PD1 antibody.
The Phase I/II trial is slated to evaluate the safety and efficacy of Nanobiotix’s NBTXR3 product administered with checkpoint inhibitors in three groups of patients with recurrent or metastatic head and neck squamous cell carcinoma or with metastatic non-small cell lung cancer.
Get the full story at our sister site, Drug Delivery Business News.
The post Nanobiotix’s nanoparticle-immunotherapy trial wins FDA approval appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Food & Drug Administration (FDA) Oncology Pharmaceuticals Wall Street Beat nanobiotix Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Head and Neck Cancer | HNSCC | Immunotherapy | Lung Cancer | Medical Devices | Nanotechnology | Non-Small Cell Lung Cancer | Skin Cancer | Squamous Cell Carcinoma